REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy

Neuro-Oncology

Volumn 11, Issue 6, 2009, Pages 790-802

  Wang, Huibo ^a,b   Zhang, Shu Yu ^b   Wang, Shuai ^c   Lu, Juan ^b   Wu, Wenting ^b   Weng, Lin ^c   Chen, Dan ^b   Zhang, Yu ^b   Lu, Zhipeng ^b   Yang, Jingmin ^b   Chen, Yuanyuan ^b   Zhang, Xu ^a   Chen, Xiaofeng ^a   Xi, Caihua ^d   Lu, Daru ^b   Zhao, Shiguang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; Glioma; REV3L; RNAi

Indexed keywords

CISPLATIN; DNA POLYMERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN REV3L; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE REPRESSION; GLIOMA; HUMAN; MALE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; CELL PROLIFERATION; CHILD; CISPLATIN; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE THERAPY; GLIOMA; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 70349302817     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2009-015     Document Type: Article

References (46)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003;361:323-331.
2. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683-2710.
3. Barzon L, Zanusso M, Colombo F, Palu G. Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther. 2006;13:539-554.
4. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
5. Okada H, Pollack IF. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther. 2004;4:1609-1620.
6. Morelli C, Mungall AJ, Negrini M, Barbanti-Brodano G, Croce CM. Alternative splicing, genomic structure, and fine chromosome localization of REV3L. Cytogenet Cell Genet. 1998;83:18-20.
7. Gibbs PE, McGregor WG, Maher VM, Nisson P, Lawrence CW. A human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the catalytic subunit of DNA polymerase zeta. Proc Natl Acad Sci U S A. 1998;95:6876-6880.
8. Kawamura K, O-Wang J, Bahar R, et al. The error-prone DNA polymerase zeta catalytic subunit (Rev3) gene is ubiquitously expressed in normal and malignant human tissues. Int J Oncol. 2001;18:97-103.
9. Xiao W, Lechler T, Chow BL, et al. Identification, chromosomal mapping and tissue-specific expression of hREV3 encoding a putative human DNA polymerase zeta. Carcinogenesis. 1998;19:945-949.
10. Okada T, Sonoda E, Yoshimura M, et al. Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol. 2005;25:6103-6111.
11. Sonoda E, Okada T, Zhao GY, et al. Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. EMBO J. 2003;22:3188-3197.
12. Van Sloun PP, Varlet I, Sonneveld E, et al. Involvement of mouse Rev3 in tolerance of endogenous and exogenous DNA damage. Mol Cell Biol. 2002;22:2159-2169.
13. Cheung HW, Chun AC, Wang Q, et al. Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res. 2006;66:4357-4367.
14. Nelson JR, Lawrence CW, Hinkle DC. Thymine-thymine dimer bypass by yeast DNA polymerase zeta. Science. 1996;272:1646-169.
15. Albertella MR, Lau A, O'Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair. 2005;4:583-593.
16. Grossman SA, Wharam M, Sheidler V, et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol. 1997;15:2596-2603.
17. DeAngelis LM. Chemotherapy for brain tumors-a new beginning. N Engl J Med. 2005;352:1036-1038.
18. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 2002;3:397-406.
19. Fruehauf JP, Brem H, Brem S, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 2006;12:4523-4532.
20. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A. 1998;95:5724-5729.
21. Lin X, Okuda T, Trang J, Howell SB. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2006;69:1748-1754.
22. Okuda T, Lin X, Trang J, Howell SB. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol. 2005;67:1852-1860.
23. Wu F, Lin X, Okuda T, Howell SB. DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res. 2004;64:8029-8035.
24. Lin X, Trang J, Okuda T, Howell SB. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res. 2006;12:563-568.
25. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-229.
26. Chiu RK, Brun J, Ramaekers C, et al. Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. PLoS Genet. 2006;2:e116.
27. Asakura T, Ohkawa K. Chemotherapeutic agents that induce mitochondrial apoptosis. Curr Cancer Drug Targets. 2004;4:577-590.
28. Robertson JD, Orrenius S. Role of mitochondria in toxic cell death. Toxicology. 2002;181-182:491-496.
29. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000;97:7124-7129.
30. Manero F, Gautier F, Gallenne T, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 2006;66:2757-2764.
31. Maher VM, McCormick JJ. The HPRT gene as a model study for mutation analysis. In: Pfeifer GP, ed. Technologies for Detection of DNA Damage and Mutations. New York: Plenum; 1996:381-390.
32. Lehmann AR. Translesion synthesis in mammalian cells. Exp Cell Res. 2006;312:2673-2676.
33. Andersen PL, Xu F, Xiao W. Eukaryotic DNA damage tolerance and translesion synthesis through covalent modifications of PCNA. Cell Res. 2008;18:162-173.
34. Lawrence CW, Hinkle DC. DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. Cancer Surv. 1996;28:21-31.
35. Liu G, Chen X. DNA polymerase eta, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates the DNA damage checkpoint and p53 activation. Mol Cell Biol. 2006;26:1398-1413.
36. Yuan B, Xu Y, Woo JH, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006;12:405-410.
37. Rimkus C, Friederichs J, Rosenberg R, Holzmann B, Siewert JR, Janssen KP. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int J Cancer. 2007;120:207-211.
38. O-Wang J, Kawamura K, Tada Y, et al. DNA polymerase kappa, implicated in spontaneous and DNA damage-induced mutagenesis, is overexpressed in lung cancer. Cancer Res. 2001;61:5366-5369.
39. Pan Q, Fang Y, Xu Y, Zhang K, Hu X. Downregulation of DNA polymerases kappa, eta, iota, and zeta in human lung, stomach, and colorectal cancers. Cancer Lett. 2005;217:139-147.
40. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312:71-80.
41. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 2001;35:161-204.
42. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the bloodtumor barrier. Cancer Res. 2005;65:11419-11428.
43. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173-184.
44. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interferencemediated gene silencing of pleiotrophin through polyethyleniminecomplexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751-766.
45. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;13:372-377.
46. Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev. 2007;59:141-152.